Coronavirus

Fully vaccinated participants experienced an 80% reduction in symptomatic disease.

The study was the largest of its kind looking at the flu shot and COVID-19.

The severity and number of symptoms varied widely between individuals.

Emergency authorization may be complete before the end of August, ensuring more protection for patients burdened with certain chronic diseases.

Recent breakthrough infections have experts looking closely at the true risks of the COVID-19 delta variant and how we can protect ourselves.

Findings also showed that women had a lower risk of testing positive than men.

With the US federal government health agencies discussing plans for a booster dose for Americans and WHO’s call for a moratorium on these shots, a tale of two vaccine strategies is emerging.

The report of promising phase 2 findings align with word that an FDA submission will be delayed until later this year.

What risks and benefits need to be considered with the return of in-person classes?

Although news of the delta variant has been front and center, the lambda variant in South America is another strain that public health officials are watching.

Reviewers attribute less severe COVID-19 symptoms in patients with HIV and low CD4 count to reduced capacity for immune reactions including cytokine storm.

Contagion Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the quick evolution of this variant and how vaccination rates have influenced this COVID-19 strain.

With the FDA nod, Regeneron’s monoclonal antibody Regen-Cov (casirivimab and imdevimab) is authorized for the use of the therapy for post-exposure prophylaxis in certain people exposed to SARS-CoV-2 or who are at high risk of exposure to an infected individual.

As the international world struggles to get first doses, the World Health Organization Director General Tedros Adhanom Ghebreyesus says this should also include high-risk populations.

A report says the timetable is for Labor Day or sooner.

Over the last 4 weeks there has been an 80% increase in the continent and the Delta variant is the large cause according to the World Health Organization (WHO).

A study looked at the efficacy of the Pfizer-BioNTech mRNA COVID-19 vaccine in a high-risk national population within a real-world setting.

Ownership language showed an additional boost in appointment and vaccination rates.

Fever was found to not be an early feature of disease.

An early warning system could help significantly help health systems and public officials to prepare.

More and more evidence is pointing towards persistent neuropsychiatric symptoms in people who had the disease.

The study found that ¾ of the cases occurred in fully vaccinated individuals.

Reasons given for not vaccinating were safety issues and low risk for infection.

A conversation with Anna Legreid Dopp, Pharm. D.

With new mask guidance comes questions and confusion, especially with the new strain of COVID-19 and those who have been vaccinated.

Last influenza season was notably quiet during peaking COVID-19 cases. Experts explain what may influence risk of dueling epidemics this year.

With its latest earnings report showing the financial impact of the vaccine, the Delta variant becoming the dominant strain in the US, and concerns of waning immunity, the company believes there is evidence for an additional booster shot.

A new report based on wearable technology finds it takes an average of 79 days for patients’ resting heart rates to return to normal following COVID-19 infection.

Commonly reported issues included delirium, encephalopathies and psychiatric complications.

Public information campaigns may potentially boost rates of vaccination.